“`html
Key News Facts
AbbVie (NYSE: ABBV) recently moved past a significant patent cliff with its former best-selling drug, Humira, and does not face another until 2037, thanks to securing patent exclusivity for its immunology medicine Rinvoq. The company has raised its dividend payouts for 53 consecutive years, with a forward yield of 2.8% and a cash payout ratio of 61.8%. AbbVie expects strong revenue growth driven by ongoing demand for its therapeutic products.
Apple (NASDAQ: AAPL) continues to expand its services business amidst challenges related to tariffs. With over 2 billion devices in circulation and more than 1 billion paid subscriptions, Apple is positioned for increased revenue in its high-margin services segment. The company has doubled its dividend in the past decade, maintaining a low cash payout ratio of 14%, allowing for further dividend increases.
“`
